Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy.

Slides:



Advertisements
Similar presentations
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Advertisements

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Treatment in Advanced Non-Small Cell Lung Cancer.
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER
Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Selecting TagSNPs in Candidate Genes for Genetic Association Studies Shehnaz K. Hussain, PhD, ScM Assistant Professor Department of Epidemiology, UCLA.
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
METHODS This project is an evidence based literature review conducted using the databases of Medline, AbstractsFirst, and Cochrane. The search terms used.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Apoptosis (Programmed Cell Death). Apoptosis vs Necrosis Level of stress, change in environment stress apoptosisnecrosis.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/2/09.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Figure S1. Quantile-quantile plot in –log10 scale for the individual studies The red line represents concordance of observed and expected values. The shaded.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
IGF-1R: A key linker between chemoresistance and cancer stem cells in epithelial ovarian cancer cells Ram Kumar Singh, Ankit Jinager, Ajit Dhadwe, Abhijit.
Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.
Heat Shock Protein 90 (HSP90) is over-expressed in p16 negative oropharyngeal squamous cell carcinoma and its inhibition in vitro potentiates the effects.
Fernando Cotait Maluf Diretor do Departamento de Oncologia Clínica Centro de Oncologia-Hospital São José Fernando Cotait Maluf Diretor.
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz 1, Sherry X. Yan 2, Tony Wang 1, Clifford Chao 1,
Homework #3 is due 11/15 Bonus #2 is posted No class on 11/20.
P53 adapted neoadjuvant therapy for esophageal cancer: Pilot study Gastrointestinal (Non colorectal) cancer Poster discussion session Sat, June 2, 2007.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.
ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.
Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.
IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.
New Proposals for Lung Cancer Staging Akif Turna, MD, PhD, FETCS Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Turkey.
A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Genetic Variations in NER Pathway, Smoking and 11 Cancer Sites: a Pooled Study Yi Ren Wang.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Merlin, tumor suppressor 박건수 Cancer Genetics.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.
EUKARYOTIC CELL SIGNALING VII Abnormal Signaling in Cancer Signaling to p53 Dr. Ke Shuai Office: 9-240M Factor Tel: X69168
PI3K inhibition does not Effect the BH3 Profile of SW620 Cells
Mouse Double Minute 2 (MDM2)
Promoter polymorphisms of the SWI/SNF chromatin remodeling complex molecule, BRM and esophageal adenocarcinoma outcome Grzegorz Korpanty1, Xin Qiu1, Lawson.
MCW Regional Cancer Therapy Program
Prognosis of younger patients in non-small cell lung cancer
Patient Case 1 Patient Case 1: PET/CT Scan.
Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
Jing Zhang, Thomas M. Roberts, Ramesh A. Shivdasani  Gastroenterology 
Treated with Neoadjuvant Therapy
高雄榮民總醫院耳鼻喉頭頸部 林陞樵 林曜祥 康柏皇 張庭碩
Overall Survival and Progression-free Survival
Successful targeting of ErbB2 receptors—is PTEN the key?
DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.
Presentation transcript:

Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy Michelle Hildebrandt, Ph.D. Instructor Department of Epidemiology

Outline Pathway Experimental Details Results Conclusions Future Directions

PI3K/PTEN/AKT/mTOR Pathway

Downstream Processes Manning and Cantley, Cell (2007) mTOR TERT

Major Effectors PI3K PTEN AKT mTOR

PI3K and PTEN “Sensor” of cellular environment – PI3K activated by receptors at membrane RTK and GPCR – Transmitted through PIP2/3 PIP3 – on PIP2 – off – PTEN removes activation signal

AKT Major adaptor protein 3 isoforms (AKT1/2/3) AKT1 and AKT2 most important for this pathway in cancer

mTOR mammalian Target Of Rapamycin (FRAP1) Involved in regulation of translation Y Mamane, et al, Oncogene (2006)

Importance in Cancer Balance between cell survival and apoptosis – Activated  Survival This pathway is often constitutively active in MANY cancers – Gene amplifications – Activating mutations – Silencing of PTEN  no regulation

Chemotherapy Response In lung and ovarian cell lines: – Overexpression of PIK3CA and reduced PTEN activity results in cisplatin resistance – Cisplatin resistance associated with AKT overexpression – Inhibition of AKT increases efficacy of paclitaxel – Inhibition of mTOR increases cisplatin efficacy – Increased AKT activity found to increase response to 5-FU

Esophageal Cancer Estimated >16,000 new EC cases each year in the US Rate of adenocarcinoma increasing rapidly – Mirror rates of obesity  gastroreflux Surgery is standard treatment Multimodal approaches are often used – 5-year survival rate of 25-28%

Esophageal Cancer Phosphorylation of AKT increased during progression from Barrett’s to EC PI3K/PTEN/AKT/mTOR Pathway is activated in EC

The Question For EC patients treated with a taxane, fluoropyrimidine and/or platinum agent… Is genetic variation within the PI3K/PTEN/AKT/mTOR pathway associated with variation in clinical outcomes?

Experimental Details Patient Characteristics 186 Caucasian patients with resectable adenocarcinoma or squamous cell carcinoma Recruited between 1985 and 2003 at MDACC Concurrent chemoradiotherapy followed by surgery, or induction chemotherapy followed by concurrent chemoradiotherapy and then surgery

Experimental Details Patient Characteristics

Study endpoints were: – Overall Survival – Recurrence – Pathologic Response to Therapy Adjusted all analyses for: – Age at diagnosis, gender, smoking status, alcohol consumption, clinical stage, histological tumor type, tumor location, pathological stage and histological viability, radiation dosage, chemoradiotherapy sequence, and chemotherapy regimens

Experimental Details Treatment Information Stratified analyses by chemotherapeutic regimen – Any of the three – Fluoropyrimidine + any – Platinum compound + any – Taxane + any

Experimental Details SNP Selection tagged SNP Selection – Based on HapMap data from CEPH population Gene + 5 Kb flanking – LD tagged SNPs: r 2 > 0.8, MAF > 0.1 – tagger and LDselect

Experimental Details SNP Selection

Results 16 SNPs, 4 treatment groups, 3 clinical outcomes…

Results Recurrence Risk in Patients Treated with Any of the Three Three SNPs associated with recurrence – AKT1:rs – AKT2:rs Increased risk of recurrence All treatment groups – PTEN:rs Decreased risk of recurrence Except for platinum compound + any

Results Recurrence Risk in Patients Treated with Any of the Three

Results Recurrence-free Survival by AKT2:rs A: Any Three B: 5-FU C: Platinum agent D: Taxane

p-value95% CIHR* No Recurrence / Recurrence < / / (reference)36 / 130 # of Unfavorable Genotypes Results Recurrence Risk by Unfavorable Genotype AKT1:rs and AKT2:rs Consistent across all strata: Fluoropyrimidine - HR*: 6.36 Platinum Agent - HR*: Taxane - HR*: 83.37

Results Gene-Gene Interactions in Patients Treated with a Taxane 7 SNPs associated with Recurrence CG + GG PTEN:rs CC PIK3CA:rs TT PIK3CA:rs TT FRAP1:rs AG + GG AKT2:rs TT AKT1:rs GT + TT AKT1:rs p-value95% CIHR*

Results Survival Tree Analysis for Recurrence

Results Survival in Patients Treated with Any of the Three Both FRAP1 (mTOR) SNPs significant – Consistent except for platinum compound group Taxane Platinum CompoundFluoropyrimidine Any of the Three TT FRAP1:rs TT FRAP1:rs p-valueHR*p-valueHR*p-valueHR*p-valueHR*

Results Survival in Patients Treated with a Taxane AKT1 and AKT2 SNPs AG + GG GG AG 1(reference)AA AKT2:rs GT + TT TT GT 1(reference)GG AKT1:rs p-value95% CIHR*

Results Pathologic Response to Therapy AKT2:rs p-valueOR*p-valueOR*p-valueOR*p-valueOR* TaxanePlatinum CompoundFluoropyrimidineAny of the Three AG + GG GG AG 1 (reference) AA

Results Pathologic Response to Therapy AKT1:rs in patients treated with Any of the Three – HR*: 0.50 (0.25 – 0.99), p-value: FRAP1:rs in taxane group only – HR*: 2.76 (1.04 – 7.37), p-value: 0.042

Conclusions Genetic variation within this important pathway is important… AKT2:rs in particular – Tags 5 SNPs – Results suggest increased signaling – Functional SNP?

Conclusions PTEN variation had expected opposite effect – Counteracts other effects Differences between treatment groups – Many more in taxane group  sample size? – Less in platinum compound group

Future Directions Analyze SNPs in a control group undergoing surgery alone Same in other cancers treated with these agents? Functional studies  mechanism

Thank You! Xifeng Wu Jafer Ajani Julie Izzo Mien-Chie Huang Esophageal Study Participants Wu Laboratory